Antibodies
14 December 2009
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer11 December 2009
Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)11 December 2009
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis11 December 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care8 December 2009
Facet Biotech Presents Scientific Data Regarding Next-Generation Proprietary Protein Engineering Technologies8 December 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia8 December 2009
Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting8 December 2009
Novo Nordisk licenses IL-21 mAb and patent rights to IL-21 antibodies from ZymoGenetics8 December 2009
Final Data from Phase 2 Study Confirm High Response Rate of Micromet’s Blinatumomab in Patients with Acute Lymphoblastic Leukemia8 December 2009
Immunomedics Reports Updated Results of Subcutaneous Humanized Anti-CD20 Antibody Therapy of Lymphoma With Veltuzumab7 December 2009
Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma7 December 2009
Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day7 December 2009
Nplate(R) Data From MDS Studies Presented at ASH7 December 2009
GENMAB ANNOUNCES RG1507 UPDATE7 December 2009
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL7 December 2009
PharmAthene Presents Phase I Clinical Trial Results and New Therapeutic Animal Model Data for Protexia(R)7 December 2009
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Multiple Myeloma4 December 2009
Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron PharmaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports